Updated Feb. 10, 2014 at 8:04 a.m.

Premium Lock Pain drug firm BioDelivery Sciences raising $60M in stock sale

Published: 2014-02-10 07:54:00
Updated: 2014-02-10 08:04:30


Capitalizing on news that its chronic pain drug BEMA buprenorphine showed positive top-line phase III clinical trial results, BioDelivery Sciences International is raising $60 million to finance commercialization efforts....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders